secwatch.observer — SEC 8-K summary
======================================

Issuer:     INSMED Inc (INSM)
CIK:        0001104506
Form:       8-K
Filed at:   2025-10-30T23:59:59+00:00
Accession:  0001140361-25-039789
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Insmed Q3 revenue $142.3M (+52% YoY); net loss $370M; BRINSUPRI launch $28.1M; raises ARIKAYCE guidance
--------------------------------------------------------------------------------

- ARIKAYCE global revenue $114.3M (+22% YoY); 2025 guidance raised to $420M-$430M.
- BRINSUPRI (brensocatib) launched post-FDA approval, Q3 revenue $28.1M; EU positive CHMP opinion.
- Net loss $370M ($1.75/shr) vs $220.5M ($1.27/shr) YoY, driven by higher R&D and SG&A for launch.
- Cash and securities $1.7B; plans continued investment across pipeline (brensocatib, TPIP, gene therapy).
- Upcoming catalysts: Ph2b BiRCh data (CRSsNP) by early Jan 2026; CEDAR (HS) data H1 2026; PALM-ILD start Q4.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1104506/000114036125039789/0001140361-25-039789-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1104506/000114036125039789/ef20057768_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-039789

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer